

# **Donanemab licensed for early stages of Alzheimer's disease in adult patients who have one or no copies of apolipoprotein E4 gene**

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a licence for the medicine donanemab (Kisunla) for use in the early stages of Alzheimer's disease, following a thorough revi...